SynthesisSaudi medical journal2025
Association between triptan use and ischemic events in patients with ischemic risk factors: A meta-analysis.
Synthesis in Saudi medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the relationship between ischemic events and triptan use in patients having ischemic risk factors and evaluate the safety profile of these medications in vulnerable individuals.
methodsA detailed search was done using Web of Science, Google Scholar, PubMed, and Medline, up to December 2024. Inclusion criteria encompassed studies focusing on triptan use in individuals having predisposing ischemic risk factors and comparing the incidence of ischemic events between those who use triptans and those who do not. Studies were excluded if they targeted patients without ischemic risk factors, did not assess triptan use, or lacked a comparative analysis between users of triptans and non-users.
resultsFrom an initial pool of 1,615 articles, f4 studies with a total sample size of 426,840 were involved in the study. The analysis revealed no significant statistical relationship between triptan use and ischemic events in patients with ischemic risk factors. Subgroup analysis of Ischemic Stroke (95% CI=0.70-8.78;
conclusionOur findings indicate that the use of triptan is not linked to a higher risk of ischemic events, indicating that triptans can be a safe therapeutic option for managing migraines in patients with ischemic risk factors. Nevertheless, Additional research is required to assess the long-term safety of triptans, particularly in high-risk populations. Limitations include the inclusion of only four studies, a limited body of literature available for comparison, and discrepancies in follow-up durations across the included studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.